Stephen Keith, PA
Medical · Texarkana, TXNPI 1376878926
Payments from drug & device makers
Across 620 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$2K
- Lilly USA, LLC$1K
- Pfizer$704
- GSK$680
- Amgen$446
- plus $3K from 30 others
What the payments were for
- Food & beverage$9,862100%
- Education$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 83 | $1,797 |
| AbbVie(2 entities) | 127 | $1,707 |
| Lilly USA, LLC | 90 | $1,317 |
| Pfizer | 50 | $704 |
| GSK | 55 | $680 |
| Amgen | 29 | $446 |
| Novo Nordisk | 25 | $407 |
| Merck | 17 | $258 |
| Mylan Specialty L.p. | 14 | $253 |
| Boehringer Ingelheim | 13 | $253 |
| Johnson & Johnson | 13 | $205 |
| Sanofi-aventis U.S. LLC | 14 | $196 |
| Amarin Pharma, Inc. | 12 | $188 |
| Idorsia Pharmaceuticals US Inc | 9 | $143 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $127 |
| Novartis | 5 | $111 |
| Corcept Therapeutics | 3 | $109 |
| Phathom Pharmaceuticals, Inc. | 5 | $102 |
| Bayer | 5 | $99 |
| Abbott | 5 | $92 |
| E.r. Squibb & Sons, L.L.C. | 6 | $83 |
| Exact Sciences | 4 | $79 |
| Boston Scientific | 3 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $74 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Kowa Pharmaceuticals America, Inc. | 3 | $52 |
| Eisai Inc. | 3 | $47 |
| Nevro Corp. | 2 | $46 |
| Astellas Pharma US Inc | 2 | $34 |
| Vifor Pharma, Inc. | 1 | $29 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Genentech USA, Inc. | 2 | $24 |
| Optinose US, Inc. | 1 | $21 |
| Almatica Pharma LLC | 1 | $21 |
| IBSA Pharma Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,907 in reported general payments places this provider in the 90th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $84,707 |
| EliquisApixaban | 80 | $68,464 |
| FarxigaDapagliflozin Propanediol | 74 | $63,100 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $42,191 |
| MounjaroTirzepatide | 38 | $41,022 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $40,482 |
| TrulicityDulaglutide | 35 | $37,112 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 57 | $35,868 |
| JardianceEmpagliflozin | 36 | $35,214 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $34,970 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $18,796 |
| EntrestoSacubitril/Valsartan | 22 | $18,179 |
| TopamaxTopiramate | 11 | $17,328 |
| UbrelvyUbrogepant | 16 | $16,808 |
| Spiriva RespimatTiotropium Bromide | 27 | $15,855 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $1,797 | $98,968131 claims |
| Novo NordiskOzempic | $407 | $84,70760 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,317 | $78,13473 claims |
| PfizerEliquis | $704 | $68,46480 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $253 | $51,06963 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $680 | $47,17270 claims |
| NovartisEntresto | $111 | $18,17922 claims |
| AbbVieUbrelvy | $1,707 | $16,80816 claims |
| Astellas Pharma US IncMyrbetriq | $34 | $13,97417 claims |
| MerckBelsomra | $258 | $10,14816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,490 medical providers in Texas.
Other medical in Texarkana
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Courtney AldridgeSan Antonio$129K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.